Screener
Madrigal Pharmaceuticals, Inc. MDGL Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Restricted cash | 155 | 5,090 |
| Marketable securities | 546,027 | 784,866 |
| Trade receivables, net | 192,311 | 134,476 |
| Inventory | 99,391 | 74,841 |
| Prepaid expenses and other current assets | 68,570 | 47,804 |
| Total current assets | 1,199,180 | 1,245,770 |
| Property and equipment, net | 11,592 | 1,499 |
| Intangible assets, net | 7,187 | 7,381 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s inventories?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported inventories of $99.39M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s inventories changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s inventories increased by 56.5% year-over-year, from $63.5M to $99.39M.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude